NASDAQ:MGTX MeiraGTx (MGTX) Stock Price, News & Analysis $7.30 +0.47 (+6.88%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$7.55 +0.25 (+3.42%) As of 02/21/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About MeiraGTx Stock (NASDAQ:MGTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MeiraGTx alerts:Sign Up Key Stats Today's Range$6.87▼$7.8050-Day Range$5.71▼$7.3052-Week Range$3.85▼$7.80Volume953,959 shsAverage Volume231,080 shsMarket Capitalization$570.50 millionP/E RatioN/ADividend YieldN/APrice Target$23.50Consensus RatingBuy Company OverviewMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Read More… MeiraGTx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreMGTX MarketRank™: MeiraGTx scored higher than 90% of companies evaluated by MarketBeat, and ranked 94th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMeiraGTx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMeiraGTx has received no research coverage in the past 90 days.Read more about MeiraGTx's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MeiraGTx are expected to grow in the coming year, from ($1.48) to $0.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MeiraGTx is -6.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MeiraGTx is -6.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioMeiraGTx has a PEG Ratio of 0.37. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioMeiraGTx has a P/B Ratio of 3.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MeiraGTx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.66% of the outstanding shares of MeiraGTx have been sold short.Short Interest Ratio / Days to CoverMeiraGTx has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in MeiraGTx has recently increased by 4.00%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMeiraGTx does not currently pay a dividend.Dividend GrowthMeiraGTx does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.54 Percentage of Shares Shorted2.66% of the outstanding shares of MeiraGTx have been sold short.Short Interest Ratio / Days to CoverMeiraGTx has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in MeiraGTx has recently increased by 4.00%, indicating that investor sentiment is decreasing. News and Social Media1.8 / 5News Sentiment0.15 News SentimentMeiraGTx has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for MeiraGTx this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added MeiraGTx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MeiraGTx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $382,838.00 in company stock.Percentage Held by InsidersOnly 8.40% of the stock of MeiraGTx is held by insiders.Percentage Held by Institutions67.48% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MeiraGTx's insider trading history. Receive MGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MeiraGTx and its competitors with MarketBeat's FREE daily newsletter. Email Address MGTX Stock News HeadlinesMeiraGTx Shares Hit 52-Week High After Blindness-Treatment Data ReleaseFebruary 21 at 4:16 PM | marketwatch.comMeiraGTx announces publication of data on rAAV8.hRKp.AIPL1 efficacyFebruary 21 at 4:16 PM | markets.businessinsider.comDOGE To DO ListElon's found so much waste he's now claiming "the magnitude of the fraud in federal entitlements" is greater than "the combined sum of every private scam you've ever heard by FAR"... And while this is disturbing and even infuriating to see our tax money literally wasted... there IS a solution. I believe it's Elon's ultimate end game.February 24, 2025 | Altimetry (Ad)MeiraGTx rises after publication of positive data from gene therapy trial for eye disorderFebruary 21 at 4:16 PM | msn.comMeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal DystrophyFebruary 21 at 6:30 AM | globenewswire.comMeiraGTx Holdings plc's (NASDAQ:MGTX) top owners are private equity firms with 25% stake, while 21% is held by institutionsJanuary 30, 2025 | finance.yahoo.comMeiraGTx's AAV8-RK-RetGC Program Gets FDA's Rare Pediatric Disease DesignationJanuary 22, 2025 | markets.businessinsider.comMeiraGTx receives RPDD from FDA for AAV8-RK-RetGC programJanuary 22, 2025 | markets.businessinsider.comSee More Headlines MGTX Stock Analysis - Frequently Asked Questions How have MGTX shares performed this year? MeiraGTx's stock was trading at $6.09 on January 1st, 2025. Since then, MGTX stock has increased by 19.9% and is now trading at $7.30. View the best growth stocks for 2025 here. How were MeiraGTx's earnings last quarter? MeiraGTx Holdings plc (NASDAQ:MGTX) released its quarterly earnings results on Monday, August, 12th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.45. The business earned $0.28 million during the quarter, compared to analyst estimates of $16.38 million. MeiraGTx had a negative net margin of 633.05% and a negative trailing twelve-month return on equity of 146.38%. When did MeiraGTx IPO? MeiraGTx (MGTX) raised $75 million in an initial public offering (IPO) on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager. Who are MeiraGTx's major shareholders? MeiraGTx's top institutional shareholders include Sanofi (15.61%), Adage Capital Partners GP L.L.C. (6.44%), Prosight Management LP (5.62%) and 683 Capital Management LLC (3.09%). Insiders that own company stock include Perceptive Advisors Llc, Alexandria Forbes, Richard Giroux, Robert K Zeldin and Robert J Wollin. View institutional ownership trends. How do I buy shares of MeiraGTx? Shares of MGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MeiraGTx own? Based on aggregate information from My MarketBeat watchlists, some other companies that MeiraGTx investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Moderna (MRNA). Company Calendar Last Earnings8/12/2024Today2/24/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MGTX CUSIPN/A CIK1735438 Webwww.meiragtx.com Phone(646) 860-7985FaxN/AEmployees300Year FoundedN/APrice Target and Rating Average Stock Price Target$23.50 High Stock Price Target$36.00 Low Stock Price Target$11.00 Potential Upside/Downside+221.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth0.37Net Income$-84,030,000.00 Net Margins-633.05% Pretax Margin-633.05% Return on Equity-146.38% Return on Assets-53.05% Debt Debt-to-Equity Ratio0.86 Current Ratio2.34 Quick Ratio2.34 Sales & Book Value Annual Sales$14.02 million Price / Sales40.69 Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book3.36Miscellaneous Outstanding Shares78,150,000Free Float71,588,000Market Cap$570.50 million OptionableOptionable Beta1.25 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:MGTX) was last updated on 2/24/2025 by MarketBeat.com Staff From Our PartnersIgnore Fox Business’s “man who calls it all” at your perilThis is the biggest AI investment story you’ve never been told… and people who invest before March 19 could st...The Oxford Club | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredWatch This Robotics Demo Before March 17thJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredNew powers for ElonAccording to one Boston think tank, which has connections in almost every major Wall Street institution, Elon ...Altimetry | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MeiraGTx Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share MeiraGTx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.